LABP Landos Biopharma
- 22.4500
- +0.2450+1.10%
- 22.3000
- -0.1500-0.67%
Landos Biopharma News
Landos Biopharma's Latest Deal Faces Tough Regulatory Gauntlet: HSR Act and FTC Scrutiny May Impose Delays and Costs
Landos Biopharma | 10-Q: Quarterly report
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
Friday, AbbVie Inc (NYSE:ABBV) reported first-quarter adjusted EPS of $2.31, down 6.1% Y/Y, beating the consensus of $2.23.Net revenues reached $12.31 billion, up 0.7%, beating the consensus of $11.92
Stockholder Alert: Ademi LLP Continues Investigation of the Fairness of Landos Biopharma, Inc.'s Transaction With AbbVie
MILWAUKEE, April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ: LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its trans
Landos Biopharma Cut to Neutral From Buy by HC Wainwright & Co.
Landos Biopharma Cut to Neutral From Buy by HC Wainwright & Co.
HC Wainwright & Co. Downgrades Landos Biopharma to Neutral, Lowers Price Target to $20.42
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Landos Biopharma (NASDAQ:LABP) from Buy to Neutral and lowers the price target from $50 to $20.42.
Landos Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 -4.67% HC Wainwright & Co. $50 → $20.42 Downgrades Buy → Neutral 01/06/2023 -99.53% Jefferies $
Maintaining Hold Rating on Landos Biopharma Amid Acquisition by AbbVie and Limited Upside Potential
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
Leerink Partners Remains a Hold on Landos Biopharma (LABP)
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
Sector Update: Health Care Stocks Softer in Afternoon Trading
Health care stocks were easing Monday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each shedding about 0.2%. The iShares Biotechnology ETF (IBB) decreas
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Landos Biopharma, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - March 25, 2024) - Rigrodsky Law, P.A. is investigating Landos Biopharma, Inc. ("Landos") (NASDAQ: LABP) regarding possible breaches of fiduciary duties and othe
12 Health Care Stocks Moving In Monday's Intraday Session
GainersLandos Biopharma (NASDAQ:LABP) shares rose 173.9% to $21.45 during Monday's regular session. The market value of their outstanding shares is at $66.8 million. The company's, Q4 earnings came ou
Landos (LABP) Secures AbbVie Deal: Propelling Novel Oral Therapy Development
The current surge of Landos Biopharma, Inc. (NASDAQ: LABP) shares on the US charts, marking a notable surge of 168.27% to $21.46 per share as of the last check, is attributed to a takeover bid. Today, Landos (LABP) disclosed a definitive agreement with AbbVie Inc., outlining AbbVie's intent to acquire Landos. At the forefront of ...
Shareholder Alert: Ademi LLP Investigates Whether Landos Biopharma, Inc. Has Obtained a Fair Price in Its Transaction With AbbVie
MILWAUKEE, March 25, 2024 /PRNewswire/ -- Ademi LLP is investigating Landos (NASDAQ: LABP) for possible breaches of fiduciary duty and other violations of law in its transaction with AbbVie. Click he
Crude Oil Moves Higher; US New Home Sales Fall In February
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The S
Landos Biopharma Shares Surge 178% on Takeover Deal With AbbVie
By Sabela Ojea Shares of Landos Biopharma on Monday surged 178% to $21.75 in pre-market trading after the company said it signed a deal to be acquired by AbbVie. The companies have reached a definit
Landos Biopharma's Definitive Merger With AbbVie Subsidiary
AbbVie to Acquire Landos Biopharma for About $137.5 Million
08:41 AM EDT, 03/25/2024 (MT Newswires) -- AbbVie to Acquire Landos Biopharma for About $137.5 Million Price: 178.68, Change: +0.23, Percent Change: +0.13
Analysis
Price Target
No Data
